Table 2

Odds ratios, relative risks and corresponding 95% confidence intervals (CI) for pregabalin and gabapentin versus placebo, and for pregabalin versus gabapentin in the indirect comparison using placebo as the common comparator (base-case analysis using the ITT LOCF approach)

Dose Comparison

Odds Ratio

95% CI

Relative Riska

95% CI


Pregabalin


150 mg vs. Placebo

2.75

1.73, 4.38

2.34

1.61, 3.27

300 mg vs. Placebo

4.62

3.16, 6.77

3.39

2.60, 4.29

450 mg vs. Placebob

6.26

4.33, 9.06

4.10

3.25, 5.02

600 mg vs. Placebo

7.77

5.32, 11.34

4.63

3.72, 5.58


Gabapentin


900 mg vs. Placebo

2.21

1.33, 3.68

1.97

1.29, 2.90

1200 mg vs. Placebo

2.54

1.64, 3.93

2.20

1.54, 3.04

1800 mg vs. Placebo

3.08

1.64, 5.81

2.55

1.54, 3.92

2400 mg vs. Placebo

3.54

1.48, 8.49

2.82

1.41, 4.85


Pregabalin vs. Gabapentin


150 mg vs. 900 mg

1.24

0.62, 2.48

1.21

0.64, 2.16

300 mg vs. 1200 mg

1.82

1.02, 3.25

1.68

1.02, 2.65

450 mga vs. 1800 mg

2.03

0.98, 4.23

1.84

0.98, 3.21

600 mg vs. 1800 mg

2.52

1.21, 5.27

2.19

1.19, 3.69

600 mg vs. 2400 mga

2.19

0.85, 5.69

1.96

0.86, 3.87


aThese relative-risk values would change with any change in assumption regarding the placebo response rate, currently assumed to be 10%.

b450 mg pregabalin and 2400 mg gabapentin were not studied in any of the trials; these results were calculated from the dose-response equation.

ITT = intention-to-treat; LOCF = last observation carried forward

Delahoy et al. BMC Neurology 2010 10:104   doi:10.1186/1471-2377-10-104

Open Data